Indeed, we have recently demonstrated that knockdown of BRG1 or use of a BRG1 inhibitor sensitizes triple negative breast cancer cells to commonly used chemotherapeutic agents, perhaps via modulation of ABC transporter expression [30]. This evidence concerns the gene ABCG2 and triple-negative breast carcinoma.